ICAD To Host First Quarter 2014 Financial Results Conference Call On Tuesday, May 6, 2014
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of
advanced image analysis, workflow solutions and radiation therapy for
the early identification and treatment of cancer, today announced that
the Company will...
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that the Company will release financial results for the three months ended March 31, 2014, following the close of the market on Tuesday, May 6, 2014. Ken Ferry, President and Chief Executive Officer, and Kevin Burns, Chief Financial and Operating Officer, will host a conference call for investors beginning at 5:00 p.m. ET on Tuesday, May 6, 2014, to discuss the first quarter 2014 financial results and to answer questions. Shareholders and other interested parties may participate in the conference call by dialing 888-713-4214 (domestic) or 617-213-4866 (international) and entering passcode 18462844. The call also will be broadcast live on the Internet at www.streetevents.com and www.icadmed.com. A replay of the conference call will be accessible two hours after its completion through May 14, 2014 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering passcode 16435276. The call will also be archived for 90 days at www.streetevents.com and www.icadmed.com. About iCAD, Inc. iCAD is an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. iCAD offers a comprehensive range of high-performance, upgradeable CAD solutions for mammography and advanced image analysis and workflow solutions for Magnetic Resonance Imaging, for breast and prostate cancers and Computed Tomography for colorectal cancer. iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System®, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. The Xoft System is also cleared for the treatment of non-melanoma skin cancer and gynecological cancers. For more information, call 877-iCADnow, or visit www.icadmed.com. For iCAD investor relations, contact Anne Marie Fields of LHA at 212-838-3777 x6604 or via email at firstname.lastname@example.org For iCAD media inquiries, contact Rachel Gross of MSLGROUP at 781-684-0770 or via email at iCAD@mslgroup.comSafe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the Company’s significant losses and uncertainty of our ability to achieve and sustain profitability, the ability to protect patents and other proprietary rights, the ability to defend itself in litigation matters, the Company’s customers’ ability to obtain appropriate coverage, and reimbursement from third-party payors, for our products and treatments, the Company’s ability to create significant markets for its newly developed products and treatments, the Company’s dependence on a limited number of customers, the uncertainty of growth of the Company’s product markets, the risk of impairment of the Company’s goodwill or other intangible assets, the risks related to regulatory and other legal requirements, the significant costs of extensive regulatory compliance, the volatility of the Company’s operating and financial results, the risks related to the Company’s existing and future debt obligations, the possible technological obsolescence of the Company’s products, the impact of supply and manufacturing constraints or difficulties, competitive pressures and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “anticipate,” “likely,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov